Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilar is expanding its footprints worldwide with multiple collaborations. In Jan 2020, […]readmore
Tags : Coherus’
The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days […]readmore
1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated […]readmore
Shots: Innovent to receive $45M as upfront, development & regulatory milestone and royalties on sales of the therapy in the licensed territories while Coherus plans to file BLA to the […]readmore
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, […]readmore
1. Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma Published: Nov 07, 2019 | Tags: Triumvira, TAC01-CD19, Receives, FDA, Fast Track Designation, R/R, Diffuse Large B-Cell […]readmore
Shots: Bioeq to receive up front, regulatory and launch milestones with equal profit sharing. Coherus to get exclusive rights to commercialize biosimilar candidate referencing Genentech’s Lucentis with its anticipated launch […]readmore
Biosimilars
Regulatory
Coherus’ Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients
Shots: Post EU Approval, Udenyca has received FDA approval on basis of non-inferiority data including its PK, PD and immunogenicity in 600 healthy patients, receiving myelosuppressive CT having cancer Udenyca […]readmore